- Home
- ATHA vs EDSA Comparison
ATHA vs EDSA Comparison
Compare ATHA & EDSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ATHA
- EDSA
- Stock Information
- Founded
- ATHA 2011
- EDSA 2015
- Country
- ATHA United States
- EDSA Canada
- Employees
- ATHA N/A
- EDSA N/A
- Industry
- ATHA Medicinal Chemicals and Botanical Products
- EDSA Biotechnology: Pharmaceutical Preparations
- Sector
- ATHA Health Care
- EDSA Health Care
- Exchange
- ATHA Nasdaq
- EDSA Nasdaq
- Market Cap
- ATHA 14.8M
- EDSA 15.4M
- IPO Year
- ATHA 2020
- EDSA N/A
- Fundamental
- Price
- ATHA $0.40
- EDSA $2.40
- Analyst Decision
- ATHA Hold
- EDSA Strong Buy
- Analyst Count
- ATHA 3
- EDSA 2
- Target Price
- ATHA $0.50
- EDSA $13.00
- AVG Volume (30 Days)
- ATHA 133.3K
- EDSA 21.6K
- Earning Date
- ATHA 08-07-2025
- EDSA 08-08-2025
- Dividend Yield
- ATHA N/A
- EDSA N/A
- EPS Growth
- ATHA N/A
- EDSA N/A
- EPS
- ATHA N/A
- EDSA N/A
- Revenue
- ATHA N/A
- EDSA N/A
- Revenue This Year
- ATHA N/A
- EDSA N/A
- Revenue Next Year
- ATHA N/A
- EDSA N/A
- P/E Ratio
- ATHA N/A
- EDSA N/A
- Revenue Growth
- ATHA N/A
- EDSA N/A
- 52 Week Low
- ATHA $0.22
- EDSA $1.55
- 52 Week High
- ATHA $3.51
- EDSA $5.00
- Technical
- Relative Strength Index (RSI)
- ATHA 53.29
- EDSA 63.71
- Support Level
- ATHA $0.38
- EDSA $2.02
- Resistance Level
- ATHA $0.41
- EDSA $2.48
- Average True Range (ATR)
- ATHA 0.02
- EDSA 0.12
- MACD
- ATHA -0.00
- EDSA 0.02
- Stochastic Oscillator
- ATHA 71.70
- EDSA 82.61
About ATHA Athira Pharma Inc.
Athira Pharma Inc is a late clinical-stage biopharmaceutical company focused on developing small molecules engineered to restore neuronal health and slow neurodegeneration. Its pipeline candidates are; Fosgonimeton (ATH-1017) is a small molecule drug candidate designed to enhance the activity of the neurotrophic hepatocyte growth factor (HGF) system; ATH-1020 a novel, orally available, next-generation small molecule drug candidate designed to positively modulate the neurotrophic HGF system; ATH-1105 is a novel, orally available, next-generation, small molecule drug candidate designed to positively modulate the neurotrophic HGF system.
About EDSA Edesa Biotech Inc.
Edesa Biotech Inc is a biotechnology company focused on inflammatory and immune-related diseases. It is involved in exploring novel ways to treat these diseases, including alternatives to topical steroids, which can have side effects. The company's product candidate, EB06, is an anti-CXCL10 monoclonal antibody candidate and is being developed as a therapy for vitiligo, a common autoimmune disorder that causes the skin to lose its color in patches. The other drug candidates in its product pipeline include EB05, EB07, and EB01 which are in their different phases of development.